Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17679365 | 0.92 | USP2 (0.31) | ALDH1A1ALOX15LMNA | |
| SCHEMBL4996746 | 0.83 | CACNA1B (0.40) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL9998013 | 0.83 | CACNA1B (0.40) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL221749 | 0.73 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL74779 | 0.73 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL271027 | 0.73 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL9773798 | 0.72 | HDAC2 (0.39) | ALDH1A1LMNA | |
| SCHEMBL16467285 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL11039206 | 0.69 | ALDH1A1 (0.46) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL11039208 | 0.69 | ALDH1A1 (0.46) | ALDH1A1ALOX15LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-07-14 | — | — | US | disclosed |
| US-11331656-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331656-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | PPOX, CYBA, CYBB | ALDH1A1 1395/4885ALOX15 18/4885LMNA 4173/4885 |
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | PPOX, CYBA, CYBB | ALDH1A1 1395/4885ALOX15 18/4885LMNA 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.